drugset / Trial / NCT06334094
Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS
Phase 4
Withdrawn
The University of Texas at Dallas
Texas Institute for Neurological Disorders · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to investigate the cognitive benefits of ozanimod in individuals with Multiple Sclerosis (MS). The study aims to understand the neural basis of cognitive improvement in Relapsing-Remitting MS patients under ozanimod treatment using neuroimaging and behavioral techniques to characterize the brain and behavioral changes due to ozanimod treatment.
Timeline
- Start
- 2024-06-01
- Primary completion
- 2028-03-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ozanimod | Small molecule | 0.92 mg | — |